Press release
Duchenne Muscular Dystrophy Drugs Market worth $2.80 billion by 2030, growing at a CAGR of 8.61% - Exclusive Report by 360iResearch
Duchenne Muscular Dystrophy Drugs Market | 360iResearch
The Global Duchenne Muscular Dystrophy Drugs Market to grow from USD 1.57 billion in 2023 to USD 2.80 billion by 2030, at a CAGR of 8.61%.
Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/duchenne-muscular-dystrophy-drugs?utm_source=openpr&utm_medium=referral&utm_campaign=sample
The Duchenne muscular dystrophy (DMD) drugs market focuses on the sales, development, and production of pharmaceuticals specifically aimed at treating DMD, a genetic disorder characterized by progressive muscle degeneration and weakness. Advancements in genetic research and breakthroughs in understanding the genetic basis of DMD are leading to more targeted and effective treatments, contributing to the market expansion. Higher global healthcare expenditure enables better treatment access for DMD, contributing to market growth. Funding and initiatives by governments and non-profit organizations boost research and development efforts, enhancing the market adoption of DMD drugs. Stringent regulatory requirements for drug approval and market introduction may delay access to innovative treatments, posing challenges in the market space. Moreover, ongoing advancements in gene editing technologies such as CRISPR/Cas9 and other gene-editing tools offer potential for curative treatments of Duchenne muscular dystrophy. The development of personalized medicine approaches tailored to individual genetic profiles may improve efficacy and minimize side effects, generating opportunities for market growth.
In the Americas region, the United States and Canada are pivotal due to the strong presence of key players engaged in developing Duchenne Muscular Dystrophy (DMD) drugs. The Americas region is characterized by high consumer awareness, substantial investments in R&D, and favorable government policies. The United States holds a key position in developing breakthrough therapies and has several patents filed for innovative DMD treatments. Canada demonstrates strong governmental support and public-private partnerships, fostering growth in the market arena. The European Union countries are at the forefront regarding regulatory support for DMD drug development and have several initiatives supporting research and access to treatment. Patent activity is high in the EMEA region, with several countries contributing to discoveries. The Middle East region, although smaller in terms of market size, is witnessing increased investment and growing awareness. Africa faces challenges related to healthcare infrastructure and treatment access and shows potential for growth through international partnerships and investments. The Asia Pacific region, especially China, Japan, and India, has grown significantly in the DMD drugs market. The market growth in the APAC countries is attributed to increasing awareness, governmental initiatives, and improving healthcare infrastructure. Research and investment in APAC countries have been robust, with Japan leading in innovative therapies and patent filings. China and India are rapidly advancing in research and offering cost-effective treatments, significantly affecting market dynamics and customer purchasing behaviors.
Market Segmentation & Coverage:
This research report categorizes the Duchenne Muscular Dystrophy Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:
Based on Drug Type, market is studied across Casimersen, Deflazacort, Delandistrogene Moxeparvovec, Eteplirsen, Golodirsen, and Viltolarsen. The Eteplirsen is projected to witness significant market share during forecast period.
Based on Administration Method, market is studied across Oral and Parental. The Oral is projected to witness significant market share during forecast period.
Based on End-Use, market is studied across Ambulatory Centres, Homecare Settings, and Hospitals & Clinics. The Hospitals & Clinics is projected to witness significant market share during forecast period.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 39.27% in 2023, followed by Europe, Middle East & Africa.
Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/duchenne-muscular-dystrophy-drugs?utm_source=openpr&utm_medium=referral&utm_campaign=inquire
FPNV Positioning Matrix:
The FPNV Positioning Matrix is essential for assessing the Duchenne Muscular Dystrophy Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).
Market Share Analysis:
The Market Share Analysis offers an insightful look at the current state of vendors in the Duchenne Muscular Dystrophy Drugs Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.
Key Company Profiles:
The report delves into recent significant developments in the Duchenne Muscular Dystrophy Drugs Market, highlighting leading vendors and their innovative profiles. These include Anuh Pharma Limited, Arlak Biotech Pvt.Ltd., Aurigene Pharmaceutical Services Ltd., Bayer Pharmaceutical, Cipla Inc., Enomark, Glasier Wellness, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Leo Pharma, Lifecare Neuro Products Limited, Mankind Pharma Ltd., Merck & Co., Inc.,, MODASA Pharmaceuticals Pvt. Ltd., Novartis AG, Pfizer Inc., QndQ Derma, RayBiotech, Inc., Ronyd Healthcare Pvt Ltd., Sarepta Therapeutics, Inc., Sumitomo Corporation, Texas Pharmaceuticals Pvt. Ltd., Wallace Pharmaceuticals Pvt Ltd., Wellona Pharma, and Zuventus Healthcare Ltd..
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Duchenne Muscular Dystrophy Drugs Market, by Drug Type
7. Duchenne Muscular Dystrophy Drugs Market, by Administration Method
8. Duchenne Muscular Dystrophy Drugs Market, by End-Use
9. Americas Duchenne Muscular Dystrophy Drugs Market
10. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market
11. Europe, Middle East & Africa Duchenne Muscular Dystrophy Drugs Market
12. Competitive Landscape
13. Competitive Portfolio
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Duchenne Muscular Dystrophy Drugs Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Duchenne Muscular Dystrophy Drugs Market?
3. What is the competitive strategic window for opportunities in the Duchenne Muscular Dystrophy Drugs Market?
4. What are the technology trends and regulatory frameworks in the Duchenne Muscular Dystrophy Drugs Market?
5. What is the market share of the leading vendors in the Duchenne Muscular Dystrophy Drugs Market?
6. What modes and strategic moves are considered suitable for entering the Duchenne Muscular Dystrophy Drugs Market?
Read More @ https://www.360iresearch.com/library/intelligence/duchenne-muscular-dystrophy-drugs?utm_source=openpr&utm_medium=referral&utm_campaign=analyst
Contact 360iResearch
Mr. Ketan Rohom
Sales & Marketing,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
sales@360iresearch.com
+1-530-264-8485
+91-922-607-7550
About 360iResearch
360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset - our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Duchenne Muscular Dystrophy Drugs Market worth $2.80 billion by 2030, growing at a CAGR of 8.61% - Exclusive Report by 360iResearch here
News-ID: 3443281 • Views: …
More Releases from 360iResearch
Rising Incidence of Human Metapneumovirus in Vulnerable Populations Boosts Globa …
In recent years, the silent ascent of human metapneumovirus (HMPV) infections has begun to capture significant attention within the realm of infectious diseases. As we advance in medical science, unraveling complexities of age-old pathogens like common influenza or emerging illnesses like COVID-19, a critical discourse has been emerging around HMPV. Particularly, there seems to be a burgeoning acknowledgment of its growing impact on vulnerable global populations, propelling an increased demand…
The Meat Alternatives Market size was estimated at USD 9.39 billion in 2023 and …
From Appetite to Advocacy: The Rising Demand for Meat Alternatives
In recent years, the global food industry has been undergoing a remarkable transformation, driven primarily by an increasing consumer demand for healthier, sustainable, and ethically sourced food products. This seismic shift has brought traditional meat alternatives and high-protein plant-based foods into the spotlight. As the world becomes more conscious of the implications of meat consumption on health and the environment, the…
The Mobility-as-a-Service Market size was estimated at USD 264.80 billion in 202 …
Unpacking the Surge in Investments and Collaborations to Bolster Mobility-as-a-Service
In recent years, as urban landscapes continually evolve, a transformative shift known as Mobility-as-a-Service (MaaS) has reshaped the way we perceive transportation. Marked by the integration of various forms of transport services into a single accessible on-demand mobility solution, MaaS is rapidly gaining traction across global cities. As an emerging paradigm, it's not just shaping the future of travel but also…
The Data Center Services Market size was estimated at USD 56.65 billion in 2023 …
Smart City Revolutions: Why Data Center Colocation is the Future Backbone
In the era of digital transformation, urban landscapes across the globe are undergoing a seismic shift toward becoming "smart cities." The concept of a smart city revolves around using digital technology, IoT (Internet of Things), AI, and data analytics at an unprecedented scale to improve urban infrastructure, manage resources efficiently, and enhance the quality of life for citizens. A vital…
More Releases for Duchenne
Emerging Trends Influencing The Growth Of The Duchenne Muscular Dystrophy (DMD) …
The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Expected to Be by 2034?
In recent times, the market size for Duchenne Muscular Dystrophy (DMD) therapeutics has seen a significant…
Rising Prevalence Of Chronic Diseases Fuels Growth In The Duchenne Muscular Dyst …
What industry-specific factors are fueling the growth of the duchenne muscular dystrophy market?
The rise in chronic diseases is projected to stimulate the expansion of the Duchenne muscular dystrophy market in the coming years. Chronic diseases are health complications that endure for a minimum of a year. Duchenne muscular dystrophy is instrumental in the increase of chronic diseases as it addresses the unique therapeutic requirements of those suffering from this genetic…
Shaping the Duchenne Muscular Dystrophy (DMD) Therapeutics Market in 2025: Bit B …
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Expected to Be, and What Will Its Growth Rate Be?
The Duchenne muscular dystrophy (DMD) therapeutics market will grow from $11.95 billion in 2024 to $16.45 billion in 2025, at a CAGR of 37.6%. The growth is attributed to the increasing prevalence of Duchenne muscular dystrophy, rising awareness of treatment options, healthcare spending, and government initiatives.
The Duchenne muscular dystrophy (DMD) therapeutics…
Duchenne Muscular Dystrophy Pipeline Outlook Report 2024
DelveInsight's, "Duchenne Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscape. It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including Duchenne Muscular Dystrophy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Duchenne Muscular Dystrophy Treatmcent Market
Global Duchenne Muscular Dystrophy Treatmcent Market Set for Robust Growth During Forecast Period
The global Duchenne Muscular Dystrophy Treatment Market is poised to witness significant growth at a high Compound Annual Growth Rate (CAGR) during the forecast period of 2023 to 2030. Duchenne muscular dystrophy (DMD) stands as a genetic disorder marked by progressive muscle degeneration and weakness, with therapeutics aimed at addressing the absence of dystrophin, a crucial protein in…
Duchenne Muscular Dystrophy (DMD) Drugs Market Report
As per the research conducted by GME, the Duchenne Muscular Dystrophy (DMD) Drugs Market will grow with a CAGR value of 41.3 percent by 2026. The global market for Duchenne muscular dystrophy is foreseen to grow due to accelerated research and development activities, expanded patient awareness for effective treatments, and the launch of new medications Moreover, the disease's increasing prominence is likely to drive the global duchenne muscular dystrophy market…
